ribociclib
novartis
['maintain trial', 'ribociclib']
 maintain trial: cdk4/6 inhibitors (#ribociclib) beyond progression (with a different endocrine partner) seem to be a "mission possible": - pfs: 5.29 vs 2.76 mo (hr 0.57, p=0.006).
- orr: 20 vs 11% (p=0.51)
- cbr: 43 vs 25% (p=0.06) #asco22 #bcareporter 